PT  - JOURNAL ARTICLE
AU  - Arabi, Yaseen
AU  - Tlayjeh, Haytham
AU  - Aldekhyl, Sara
AU  - Al-Dorzi, Hasan M
AU  - Abdukahil, Sheryl Ann
AU  - Al Harbi, Mohammad Khulaif
AU  - Haji, Husain Al
AU  - Mutairi, Mohammed Al
AU  - Zumai, Omar Al
AU  - Qasim, Eman Al
AU  - Wehaibi, Wedyan Al
AU  - Qahtani, Saad Al
AU  - Al-Hameed, Fahad
AU  - Chalabi, Jamal
AU  - Alshahrani, Mohammed
AU  - Alharthy, Abdulrahman
AU  - Mady, Ahmed
AU  - Eshaq, Abdulhadi Bin
AU  - Bshabshe, Ali Al
AU  - Aseri, Zohair Al
AU  - Duhailib, Zainab Al
AU  - Kharaba, Ayman
AU  - Alqahtani, Rakan
AU  - Ghamdi, Adnan Al
AU  - Altalag, Ali
AU  - Alghamdi, Khalid
AU  - Almaani, Mohammed
AU  - Algethamy, Haifa
AU  - Aqeily, Ahmad Al
AU  - Baseet, Faisal Al
AU  - Samannoudi, Hashem Al
AU  - Obaidi, Mohammed Al
AU  - Ismaiel, Yassin
AU  - Al-Fares, Abdulrahman A
TI  - Helmet noninvasive ventilation for COVID-19 patients “Helmet-COVID”: study protocol for a multicenter randomized controlled trial
AID  - 10.1101/2021.08.04.21260420
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.04.21260420
4099  - http://medrxiv.org/content/early/2021/08/06/2021.08.04.21260420.short
4100  - http://medrxiv.org/content/early/2021/08/06/2021.08.04.21260420.full
AB  - Introduction Noninvasive ventilation delivered by helmet is has been used for respiratory support of patients with acute hypoxemic respiratory failure due to COVID-19 pneumonia. The aim of this study is to compare helmet noninvasive ventilation with usual care versus usual care alone to reduce the mortality.Methods and analysis This is a multicenter, pragmatic, parallel, randomized controlled trial that compares helmet noninvasive ventilation with usual care to usual care alone in 1:1 ratio. A total of 320 patients will be enrolled in this study. The primary outcome is 28-day all-cause mortality. The primary outcome will be compared between the two study groups in the intention-to-treat and per-protocol cohorts. An interim analysis will be conducted for both safety and effectiveness.Ethics and dissemination Approvals are obtained from the Institutional Review Boards (IRBs) of each participating institution. Our findings will be published in peer-review journals and presented at relevant conferences and meetings.Trial registration number NCT04477668 registered on July 20, 2020Strengths and limitations of this studyThis trial compares helmet NIV to usual care for respiratory support of patients with acute hypoxemic respiratory failure due to COVID-19 pneumonia.The trial is a multi-center, pragmatic, parallel randomized controlled trial.The main limitation is the unblinded design due to the nature of the intervention.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04477668Funding StatementThe study is funded by King Abdullah International Medical Research Center (RC 20/306/R). The study sponsor does not have any role in the study design, collection, management, analysis, and interpretation of data as well as writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study has been approved by the Institutional Review Board (IRB) of Ministry of National Guard Health Affairs (MNGHA) and the respective Institutional Review Boards of Imam Abdulrahman bin Faisal University; King Saud Medical City ;King Khalid Hospital, Najran; Aseer Central Hospital; King Faisal Specialist Hospital & Research Center, Riyadh; King Fahad Hospital Madinah; King Khalid University Hospital, Riyadh; Prince Sultan Military Medical City; King Abdulaziz University Hospital Jeddah and Al Amiri Hospital Kuwait All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be provided upon reasonable request from the Chief Investigator.